Table 1.

Overview of discussed radiopharmaceuticals.

Radiopharmaceutical	Indication
[18F]-FES	Breast Cancer
[18F]-FDHT	Prostate and breast cancer
[111In]/[89Zr]-trastuzumab	Breast Cancer
[68Ga]-DOTA-TOC/TATE/NOC	Neuroendocrine tumors
[68Ga]-DOTAGA-TATE/TOC	Neuroendocrine tumors
[68Ga]-OPS202	Neuroendocrine tumors
[99mTc]-Hynic-TOC	Neuroendocrine tumors
[18F]-FES	Breast Cancer
[18F]-FDHT	Prostate and breast cancer
[111In]/[89Zr]-trastuzumab	Breast Cancer
[68Ga]-DOTA-TOC/TATE/NOC	Neuroendocrine tumors

[¹⁸F]-FES = 16α-[¹⁸F]-fluoro-17β-estradiol; [¹⁸F]-FDHT = fluorodihydrotestosterone; [⁶⁸Ga]-DOTA-Tyr-3-octreotide = DOTA-TOC; [⁶⁸Ga]-DOTA-NaI-octreotide = DOTA-NOC; [⁶⁸Ga]-DOTA-octreotate = DOTA-TATE; OPS202 = NODAGA-JR11.